Journal
EUROPEAN UROLOGY FOCUS
Volume 4, Issue 4, Pages 509-511Publisher
ELSEVIER
DOI: 10.1016/j.euf.2018.08.005
Keywords
Bladder cancer; Urothelial cancer; Photodynamic therapy; Photoimmunotherapy; PDT; PIT; Hematoporphyrin; 5-Aminolevulinic acid; Hexaminolevulinic acid; BCG-refractory NMIBC
Categories
Funding
- Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research
Ask authors/readers for more resources
There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed photoimmunotherapy, which we will discuss in the last part of this report. (C) 2018 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available